RHEUMACEPT Trademark

Trademark Overview

On Friday, July 16, 2021, a trademark application was filed for RHEUMACEPT with the United States Patent and Trademark Office. The USPTO has given the RHEUMACEPT trademark a serial number of 90833367. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Thursday, July 11, 2024. This trademark is owned by Navidea Biopharmaceuticals, Inc.. The RHEUMACEPT trademark is filed in the Pharmaceutical Products category with the following description:

Radiopharmaceutical imaging and detection agents for diagnosing and monitoring rheumatoid arthritis
rheumacept

General Information

Serial Number90833367
Word MarkRHEUMACEPT
Filing DateFriday, July 16, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateThursday, July 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 17, 2022

Trademark Statements

Goods and ServicesRadiopharmaceutical imaging and detection agents for diagnosing and monitoring rheumatoid arthritis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 20, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNavidea Biopharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressColumbus, OH 43220
Party NameNavidea Biopharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDublin, OH 43017

Trademark Events

Event DateEvent Description
Tuesday, July 20, 2021NEW APPLICATION ENTERED
Monday, September 20, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, April 6, 2022ASSIGNED TO EXAMINER
Monday, April 11, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 17, 2022PUBLISHED FOR OPPOSITION
Wednesday, April 27, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 17, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, May 23, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, May 23, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, May 23, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 10, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 12, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 10, 2023SOU EXTENSION 2 FILED
Tuesday, January 10, 2023SOU EXTENSION 1 FILED
Tuesday, January 10, 2023SOU EXTENSION 1 GRANTED
Monday, July 10, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 10, 2023SOU EXTENSION 2 GRANTED
Wednesday, July 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 1, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, July 1, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, January 11, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 11, 2024SOU EXTENSION 3 FILED
Thursday, January 11, 2024SOU EXTENSION 3 GRANTED
Saturday, January 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 1, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, July 1, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, July 1, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, July 1, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, July 11, 2024SOU TEAS EXTENSION RECEIVED
Thursday, July 11, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 11, 2024SOU EXTENSION 4 GRANTED
Thursday, July 11, 2024SOU EXTENSION 4 FILED

Related Keywords

rheumacept monitoring rheumatoid arthritis diagnosing agents imaging detection radiopharmaceutical